A J McCullough
Affiliation: Case Western Reserve University
- Pathophysiology of nonalcoholic steatohepatitisArthur J McCullough
Case Western Reserve University and Schwartz Center for Metabolism and Nutrition at MetroHealth Medical Center, Cleveland, OH 44109 1998, USA
J Clin Gastroenterol 40:S17-29. 2006..Which of the pathophysiologic factors (which are discussed in this review), either alone or in combination, will eventually provide the basis for the most effective therapy has yet to be determined...
- Update on nonalcoholic fatty liver diseaseArthur J McCullough
Division of Gastroenterology and the Robert Schwartz Center of Metabolism and Nutrition at MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio 44109 1998, USA
J Clin Gastroenterol 34:255-62. 2002..Future therapies will depend on a greater understanding of the pathophysiology and should focus on diminishing fibrosis...
- Clinical features and natural history of nonalcoholic steatosis syndromesY Falck-Ytter
Schwartz Center for Metabolism and Nutrition, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
Semin Liver Dis 21:17-26. 2001..However, a number of important unresolved issues must be clarified before the true natural history of this disease can be fully understood...
- Steatohepatitis in obese individualsWael I Youssef
Division of Gastroenterology, The Robert Schwartz Center for Metabolism and Nutrition at Metro Health Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA
Best Pract Res Clin Gastroenterol 16:733-47. 2002..Bariatric surgery is indicated in selected patients.A greater understanding of the pathophysiological progression of NASH in obese patients must be obtained in order to develop more focused and improved therapy...
- Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime timeArthur J McCullough
N Engl J Med 355:2361-3. 2006
- Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and futureAnna Wieckowska
Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Hepatology 46:582-9. 2007..They will not only help in the diagnosis of NASH, but also be useful for assessment of treatment response and prognosis and remain a research priority in the NAFLD field...
- The clinical features, diagnosis and natural history of nonalcoholic fatty liver diseaseArthur J McCullough
Case Western Reserve University, 2500 Metro Health Drive, Cleveland, OH 44109, USA
Clin Liver Dis 8:521-33, viii. 2004..The major risk factors for fibrosis include diabetes or obesity, an aspartate aminotransferase/alanine aminotransferase ratio of greater than 1, age older than 50, and hepatic histology...
- Diabetes mellitus, obesity, and hepatic steatosisWael Youssef
Division of Gastroenterology, Case Western Reserve University, Cleveland, OH, USA
Semin Gastrointest Dis 13:17-30. 2002..These include anti-oxidants such as vitamin E and betaine, bile acid therapy with ursodeoxycholic acid, and improved insulin sensitivity with metformin. Another potential therapeutic strategy is the reduction of inflammatory cytokines...
- Nonalcoholic fatty liver disease in patients with type 2 diabetesZobair M Younossi
The Cleveland Clinic Foundation, Cleveland, USA
Clin Gastroenterol Hepatol 2:262-5. 2004..The aim of this study was to assess the outcome of patients with NAFLD and DM...
- Obesity and non-alcoholic fatty liver disease in chronic hepatitis CZobair M Younossi
Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
J Clin Gastroenterol 38:705-9. 2004..Superimposed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) may affect HCV-related fibrosis. We performed a study to determine the relationship between NAFLD and chronic hepatitis C...
- Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humansSatish C Kalhan
Schwartz Center for Nutrition and Metabolism, MetroHealth Center, Cleveland, OH 44109, USA
Metabolism 57:305-12. 2008..The contribution of glyceroneogenesis to triglyceride-glycerol is not affected by short (4 hours) infusion of insulin in type 2 diabetes mellitus...
- Pathogenesis of non-alcoholic steatohepatitis: human dataJohn Edmison
Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, OH 44195, USA
Clin Liver Dis 11:75-104, ix. 2007..Although fatty liver may be caused by other factors, this review concentrates on fatty liver associated with insulin resistance, sometimes referred to as the primary form...
- Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver diseaseNaga Chalasani
Indiana University School of Medicine, 1050 Wishard Boulevard, Indianapolis, IN 46202, USA
J Hepatol 48:829-34. 2008..The relationship between severity and zonal location of steatosis and the presence of steatohepatitis and various histological features that define NASH has not been formally studied...
- Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessmentClaudia O Zein
Division of Gastroenterology and Hepatology, University Hospitals of Cleveland, Cleveland, OH, USA
Hepatology 44:1564-71. 2006..In conclusion, smoking may accelerate the progression of PBC. This could be induced by exposure to chemicals in cigarette smoke...
- In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver diseaseAnna Wieckowska
Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Hepatology 44:27-33. 2006..These data highlight the potential usefulness of this test as a noninvasive diagnostic means of determining histological disease severity in patients with NAFLD...
- Steroids or cocktails for alcoholic hepatitisRobert O'Shea
J Hepatol 44:633-6. 2006
- Insulin resistance: a metabolic pathway to chronic liver diseaseElisabetta Bugianesi
Gastroenterology Department, University of Turin, Turin, Italy
Hepatology 42:987-1000. 2005..Finally, the ability of insulin-sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed...
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseDavid E Kleiner
Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
Hepatology 41:1313-21. 2005..NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."..
- Treatment of alcoholic hepatitisRobert S O'Shea
Department of Gastroenterology and Hepatology A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Clin Liver Dis 9:103-34. 2005....
- Pathologic features associated with fibrosis in nonalcoholic fatty liver diseaseTerry Gramlich
Cleveland Clinic Foundation, OH, USA
Hum Pathol 35:196-9. 2004..We conclude that the presence of hepatocyte injury in NAFLD is associated with fibrosis. These pathological features can be used to establish the pathological criteria for diagnosis of the progressive form of NAFLD or NASH...
- Obesity and its nurturing effect on hepatitis CArthur J McCullough
Hepatology 38:557-9. 2003
- Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitisMansour A Parsi
Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Gastroenterology 135:803-7. 2008..The aim of this study was to assess the utility of ascitic fluid lactoferrin (AFLAC) for the diagnosis of SBP and to identify a cut-off level that can be used for future development of a rapid bedside test...
- NASH PROJECTArthur McCullough; Fiscal Year: 2007..abstract_text> ..